<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285125</url>
  </required_header>
  <id_info>
    <org_study_id>ALR_2019_16</org_study_id>
    <nct_id>NCT04285125</nct_id>
  </id_info>
  <brief_title>High Resolution Imaging for Analysis of MVNT</brief_title>
  <acronym>HAM</acronym>
  <official_title>High Resolution Imaging for Analysis of Multinodular and Vacuolating Neuronal Tumor of the Cerebrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MVNT (multinodular and vacuolating neuronal tumor of the cerebrum) is a benign, recently
      discovered, neuronal lesion, the incidence of which is unknown.

      It seems to predominate in the temporal lobes and presents a characteristic MRI appearance:
      multiple subcortical nodules, developed at the white substance / gray substance junction, of
      variable size, well limited, in iso-hyposignal T1, hypersignal T2 and hypersignal FLAIR.

      The articles describing this entity report the lack of scalability in MRI during patient
      monitoring, going in the direction of the benignity of the lesion.

      The diagnosis sometimes remains uncertain with current MRI sequences, and the patient risks
      undergoing invasive surgery to remove a lesion that is actually benign. Hence the importance
      of developing the most precise diagnostic criteria possible. The contribution of advanced MRI
      techniques, such as ultra-high resolution sequences in the characterization of these lesions,
      has not yet been studied.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of patients with a central T2 / FLAIR hyposignal visible on standard sequences and on ultra-high resolution sequences.</measure>
    <time_frame>Day 1</time_frame>
    <description>Among the patients with confirmation of the diagnosis of MVNT (Multinodular and Vacuolating Neuronal Tumor) on the characterization MRI</description>
  </primary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Benign Neuronal Desease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cerebral MRI</intervention_name>
    <description>Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspicion of MVNT during a first exploratory MRI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years of age

          -  Prospective inclusion of all patients with suspected MVNT on a first exploratory MRI:
             at least the 2 major criteria associated with at least 1 minor criterion will be
             required to fit into the definition of suspected MVNT:

               -  Major criteria :

                    -  Multinomodular clustered appearance

                    -  Franc hypersignal FLAIR/T2

               -  Minor criteria :

                    -  No mass effect

                    -  Hyposignal T1

          -  Having received informed information about the study and having given express consent
             to participate in the study

        Exclusion Criteria:

          -  Contraindication to MRI

          -  Patient benefiting from a legal protection measure

          -  Pregnant or breastfeeding woman

        Secondary exclusion criteria:

        - No characterization MRI done
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amelie YAVCHITZ, PhD</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Augustin Lecler</last_name>
    <phone>0148036401</phone>
    <email>alecler@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation A De Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Laennec</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Paul Riquet, CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

